<DOC>
	<DOC>NCT00475371</DOC>
	<brief_summary>26 subjects will be enrolled into 5 different dose groups. The trial will consist of a screening, a dosing and a follow-up visit. Dosing at visit 2, of MKC253 Inhalation Powder, Glucagon-Like Peptide-1 (GLP-1) will be given at 5 dose levels.</brief_summary>
	<brief_title>A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males</brief_title>
	<detailed_description>This Phase 1a , single-dose trial incorporates an open-label, ascending dose strategy to determine the safety &amp; tolerability of MKC253 (GLP1/TechnosphereÂ®)Inhalation Powder. The trial consists of a screening, dosing and a follow-up visit. Single dose administration of MKC253 occurs at the dosing visit. Five doses are being assessed: 0.05, 0.45, 0.75, 1.05 &amp; 1.5 mg GLP-1. Dosing of each ascending cohort will occur after the Principal Investigator has reviewed all safety/tolerability data</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Healthy males = 18 and = 45 years of age Written Informed Consent. Body Mass Index (BMI) of &lt; 30 kg/m2 Nonsmoker Normal pulmonary function and performance on pulmonary function tests Clinically significant disease including diabetes mellitus Fasting blood glucose &gt; 110 mg/dL (6.1 mmol/L) Significant psychiatric condition or drug or alcohol abuse Any other condition which, in the opinion of the PI, makes the subject unsuitable for the clinical trial, or could limit the validity of the informed consent and/or impair the subject's ability to participate in the trial Inability to perform PFT maneuvers meeting recommended American Thoracic Society (ATS) standards of acceptability and repeatability criteria</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Diabetes Mellitus: Type II</keyword>
</DOC>